Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on December 29, 2009, reporting events occurring on December 24, 2009. Lexaria Corp. (Lexaria Bioscience Corp.) is a Nevada corporation incorporated in Canada, focused on oil field operations, specifically the Belmont Lake Oil Field.
Key Financial Metrics
The filing details a private placement financing event rather than periodic financial statements. Key metrics from the transaction include:
- Gross Proceeds: CDN$194,130 (US$184,909).
- Units Issued: 1,617,752 units.
- Price Per Unit: $0.12.
- Warrant Terms: Each unit includes one-half of a warrant; full warrants allow purchase of one share at CDN$0.22 (US$0.21) until December 24, 2010.
- Management Participation: CEO Chris Bunka subscribed for 200,000 units.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and the issuance of unregistered securities. The company raised approximately US$185,000 to fund operations and working capital. No comparative period financial data is provided in this specific filing to assess changes in operating performance.
Outlook, Risks, and Use of Proceeds
Use of Proceeds: Funds are intended for operations at the Belmont Lake Oil Field and general working capital.
Risks and Contingencies: The securities were issued under exemptions (Rule 506 of Regulation D for US persons and Regulation S for non-US persons) and are not registered under the Securities Act of 1933. They may not be offered or sold in the United States absent registration or an applicable exemption. The filing incorporates a press release (Exhibit 99.1) for further disclosure.
Investor Verification Checklist
- Verify the current status of the Belmont Lake Oil Field operations and whether the raised capital has been deployed as intended.
- Confirm the number of outstanding shares and warrants post-issuance to assess dilution impact.
- Review the incorporated press release (Exhibit 99.1) for additional operational details not present in the 8-K text.
- Check subsequent filings for updates on the company's liquidity and ability to meet operational costs beyond the initial working capital injection.